Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for INVA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 51.97M
March 31, 2026 35.28M
December 31, 2025 54.51M
September 30, 2025 49.73M
June 30, 2025 44.07M
March 31, 2025 48.62M
December 31, 2024 59.24M
September 30, 2024 48.69M
June 30, 2024 43.72M
March 31, 2024 37.05M
December 31, 2023 33.26M
September 30, 2023 43.94M
June 30, 2023 38.18M
March 31, 2023 25.68M
December 31, 2022 8.899M
September 30, 2022 15.69M
June 30, 2022 79.04M
March 31, 2022 98.10M
December 31, 2021 98.38M
September 30, 2021 96.71M
June 30, 2021 84.61M
March 31, 2021 84.11M
December 31, 2020 85.28M
September 30, 2020 74.56M
June 30, 2020 79.79M
Date Value
March 31, 2020 73.48M
December 31, 2019 66.90M
September 30, 2019 57.40M
June 30, 2019 56.50M
March 31, 2019 76.66M
December 31, 2018 61.78M
September 30, 2018 60.12M
June 30, 2018 51.72M
March 31, 2018 49.91M
December 31, 2017 47.86M
September 30, 2017 43.49M
June 30, 2017 22.64M
March 31, 2017 27.76M
December 31, 2016 21.09M
September 30, 2016 20.19M
June 30, 2016 12.46M
March 31, 2016 7.25M
December 31, 2015 6.917M
September 30, 2015 2.656M
June 30, 2015 2.174M
March 31, 2015 -1.616M
December 31, 2014 -4.61M
September 30, 2014 -21.07M
June 30, 2014 -54.40M
March 31, 2014 -50.64M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Zevra Therapeutics, Inc. 17.03M
Collegium Pharmaceutical, Inc. 71.32M
CorMedix, Inc. 86.06M
ANI Pharmaceuticals, Inc. 56.67M
Corcept Therapeutics, Inc. 33.54M